Liver concerns scupper Takeda's fasiglifam at Phase III
This article was originally published in Scrip
Despite the release of promising initial Phase III efficacy data earlier in the year, 2013 has not ended well for Takeda's first-in-class GPR40 agonist fasiglifam (TAK-875), with the company deciding to drop the oral diabetes drug for safety reasons.
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.